Form 8-K - Current report:
SEC Accession No. 0000950170-24-028647
Filing Date
2024-03-08
Accepted
2024-03-08 16:11:29
Documents
14
Period of Report
2024-03-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K janx-20240308.htm   iXBRL 8-K 45717
2 EX-99.1 janx-ex99_1.htm EX-99.1 161519
3 GRAPHIC img201480580_0.jpg GRAPHIC 4603
  Complete submission text file 0000950170-24-028647.txt   371793

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20240308.xsd EX-101.SCH 49418
15 EXTRACTED XBRL INSTANCE DOCUMENT janx-20240308_htm.xml XML 4899
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 24734446
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)